APYX Stock — Apyx Medical Inc

Apyx Medical Inc (APYX)

Updated October 16, 2026.

APYX is a Stock. Total return is -95.3% over the past 40.4 years.

Apyx Medical designs, develops, manufactures, and sells electrosurgical equipment and medical devices used in surgical and cosmetic procedures. The company operates through two segments: Surgical Aesthetics, which markets helium plasma technology products under the Renuvion brand for cosmetic surgery and the J-Plasma brand for hospital surgical applications, and Original Equipment Manufacturing, which produces generators and accessories for other medical device makers. The company does not currently distribute to shareholders.

APYX performance

Price and return data through 2026-10-16.

Total return is -95.3% over the past 40.4 years. Over the past year its total return — price change plus distributions reinvested — is -18.0%. Its deepest 1-year drawdown was 51.4%.

APYX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/15/1986

Distribution frequency

None

Last close

$2.55 (as of 2026-10-16)

Market cap

$107,416,259

Average volume

53987.0

Beta

1.45

Payout ratio

0.0%

Forward P/E

72.4638

EPS

$-0.20

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

APYX risks and drawbacks

The deepest 1-year drawdown on record here is 51.4%.

Who may consider APYX — and who may not

It is a weaker fit for investors who need monthly cash flow (APYX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on APYX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions